Solution to medical mystery may help some children avoid bone marrow transplantation
(St. Jude Children's Research Hospital) Researchers have helped solve a decades-old mystery about which mutations are responsible for an inherited bone marrow disorder. The answer may allow some children to avoid the risk and expense of bone marrow transplantation, a common treatment for leukemia and bone marrow disorders. Investigators at St. Jude Children's Research Hospital and UCSF, led the study, which appears today in the scientific journal JCI Insight.The disorder is myelodysplasia and leukemia syndrome with monosomy 7. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 26, 2018 Category: Biology Source Type: news
PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform
(Medical University of South Carolina) The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina investigators in The Journal of Clinical Investigation. Blocking PIM-2 in allogeneic bone marrow transplant dramatically accelerated graft-versus-host disease. In adoptive immunotherapy with autologous T cells, silencing PIM-2 on T cells produced robust tumor immunity, highlighting the importance of PIM-specific inhibition. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 15, 2018 Category: Cancer & Oncology Source Type: news
Girl, 6, bravely battles two types of rare cancer and needs bone marrow transplant
Kalea Ramos, six, from San Diego, California, was diagnosed with two forms of rare leukemia last October, leaving her in need of a bone marrow transplant - and nobody in her family is a match. (Source: the Mail online | Health)
Source: the Mail online | Health - May 28, 2018 Category: Consumer Health News Source Type: news
The Healing Edge: Five Blood Transfusions, One Bone Marrow Transplant — All Before Birth
In a bold experiment in fetal therapy, doctors in San Francisco treated a fetus with a severe, often fatal blood disorder. The child was saved, but the long-term prognosis is still uncertain. (Source: NYT Health)
Source: NYT Health - May 25, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Transfusions Pregnancy and Childbirth Bone Marrow Genetics and Heredity Immune System University of California, San Francisco Source Type: news
New CAR T case study shows promise in acute myeloid leukemia
(H. Lee Moffitt Cancer Center& Research Institute) According to a case study from trial published online ahead of print in the journal Haematologica, a patient has remained cancer free for nine months after being treated with CYAD-01, followed by a bone marrow transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news
Latest Mesothelioma Immunotherapy Combination Looks Promising
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma.
The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma.
“This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in aggressive mo...
Source: Asbestos and Mesothelioma News - April 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news
Uncovering a mechanism causing chronic graft-vs-host disease after bone marrow transplant
(Medical University of South Carolina) MicroRNA-17-92 is required for the T-cell and B-cell pathogenicity that drives chronic graft-versus-host disease (cGVHD) after allogeneic bone marrow transplant (BMT), report investigators at The Medical University of South Carolina in an article prepublished online March 12, 2018 by Blood. Data from cGVHD mouse models showed that, by determining T-cell and B-cell differentiation and function, miR-17-92 is responsible for cGVHD development. Inhibiting miR-17 is a potential therapeutic strategy for preventing cGVHD in BMT patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 2, 2018 Category: Cancer & Oncology Source Type: news
Iranian man granted visa to donate bone marrow to brother in US
After almost two months, the US State Department approved a visa for an Iranian man to come to the United States in order to have bone marrow transplant surgery to help his brother, who has cancer. (Source: CNN.com - Health)
Source: CNN.com - Health - March 30, 2018 Category: Consumer Health News Source Type: news
Trump's Travel Ban Imperils U.S. Citizen With Cancer Trump's Travel Ban Imperils U.S. Citizen With Cancer
Maziar Hashemi, a naturalized U.S. citizen who lives in Massachusetts, has been told by doctors that his best hope for surviving a rare form of blood cancer is a bone marrow transplant.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 30, 2018 Category: Transplant Surgery Tags: Public Health & Prevention News Source Type: news
Trump travel ban hinders man's ability to have lifesaving surgery
President Donald Trump's travel ban is throwing up road blocks for a US citizen who needs a bone marrow transplant that could save his life. (Source: CNN.com - Health)
Source: CNN.com - Health - March 29, 2018 Category: Consumer Health News Source Type: news
Trump's travel ban imperils U.S. citizen with cancer
NEW YORK (Reuters) - Maziar Hashemi, a naturalized U.S. citizen who lives in Massachusetts, has been told by doctors that his best hope for surviving a rare form of blood cancer is a bone marrow transplant. (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
There Is No Cure for HIV —But Scientists May Be Getting Closer
Cure isn’t a word normally used in the context of AIDS. For most of the 35 years since HIV, the virus responsible for the disease, was first identified, doctors have viewed the notion of a cure as more fantasy than fact.
That’s because HIV is a virus unlike any other. It disables the very immune cells that are supposed to destroy it and also sequesters itself in the body’s cells, staging the ultimate deadly ambush whenever the immune defense’s guard comes down, months or sometimes even years later.
Yet for the first time in the HIV epidemic that currently affects nearly 37 million people worldwide, ...
Source: TIME: Health - March 8, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized AIDS/HIV Source Type: news
Release of the 7th edition of the International Standards on Hematopoietic Cell Therapy
(European Society for Blood and Marrow Transplantation) The Standards are among the only sets of professional They are produced by international experts from cellular therapy programs.The Standards address every aspect of cell collection, processing and administration that impacts on the quality of products and therapeutic care.* The Standards are considered the 'gold standard' for bone marrow transplantation. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 2, 2018 Category: Biology Source Type: news
Helpful, hopeful news for bone marrow transplant patients
(Children's National Health System) Research published online by The Lancet Haematology and co-led by Kirsten M. Williams, M.D., suggests that a new imaging agent can safely show engraftment as early as days after transplant--giving a helpful and hopeful preview to patients and their doctors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2018 Category: Cancer & Oncology Source Type: news
How Cancer Immunotherapy Is Getting Even Better
Last year, the Food and Drug Administration approved two new immunotherapies to treat certain leukemias and lymphomas. Now, in a study published in the New England Journal of Medicine, researchers detail who is most likely to benefit from the treatments, called CAR T cell therapy.
CAR T cell therapy trains the body’s immune system to target and destroy cancer cells in the blood; scientists take people’s own immune cells (T cells) and genetically engineer them to seek out and destroy cancer cells. The immune system can then attack cancer cells in the same way it does bacteria and viruses, and the therapy can lea...
Source: TIME: Health - February 2, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer cancer cells cancer immunotherapy CAR T car t cell therapy car t gene therapy car t therapy cure for cancer healthytime leukemia leukemia treatments Source Type: news
